Avidity Biosciences (RNA) Financials

Avidity Biosciences’ reported financial data shows a development-stage biotechnology company with recurring operating losses, volatile collaboration revenue and a balance sheet that has changed substantially through equity financing and investment activity. However, investors should use caution when comparing periods: the Q2 2026 statements identify the company as Atrium Therapeutics, Inc., while earlier statements identify Avidity Biosciences, Inc. The filings also include restated figures and different company identifiers, creating a potential data-continuity issue.

• Strong near-term liquidity: As of June 30, 2026, cash, restricted cash and short-term investments totaled approximately $265.2 million. Total current assets of $275.1 million exceeded total liabilities of $65.9 million by a wide margin.
• Low reported leverage: The Q2 2026 balance sheet lists no material debt or capital lease obligations. Deferred revenue represents the largest portion of noncurrent liabilities, rather than borrowings.
• Operating cash burn improved sequentially: Net cash used in operating activities declined to $3.9 million in Q2 2026 from $31.1 million in Q1. The improvement was primarily driven by a $14.5 million favorable change in operating assets and liabilities.
• Operating expenses declined: Q2 2026 selling, general and administrative expense fell to $10.3 million from $20.3 million in Q1, while research and development expense declined to $15.3 million from $16.7 million.
• Revenue remains unpredictable: Q2 2026 revenue was $3.0 million, down sharply from $19.6 million in Q1 2026 and below $3.8 million in Q2 2025. The data suggests revenue is driven by milestone, collaboration or other irregular payments rather than a stable commercial base.
• Investment balances are actively managed: Q2 2026 investing cash outflow was $191.6 million, while short-term investments stood at $191.6 million at quarter-end. This appears largely related to moving cash into investments, rather than a comparable operating investment in property or equipment.
• The company remains unprofitable: Q2 2026 net loss was $20.2 million, or $1.18 per basic and diluted share, compared with a $16.6 million loss, or $0.97 per share, in Q1. Revenue covered only a small portion of operating expenses.
• Longer-term losses and dilution are significant risks: Earlier reported periods show substantial losses, including $102.3 million in Q4 2024 and $237.1 million in Q4 2025. Equity issuance was also a recurring source of funding, including $301.5 million in Q1 2026, which can dilute existing shareholders.
• Retained earnings remain negative: Q2 2026 retained earnings were negative $8.1 million, and the company continues to rely on cash reserves, investment income and external financing rather than internally generated profits.

The most constructive development is the company’s liquidity relative to its current obligations and the sequential reduction in operating cash burn. Nevertheless, the latest quarter’s revenue decline, ongoing net losses and history of equity financing indicate that cash may continue to be consumed before the business reaches sustainable profitability.

Investors should also reconcile the apparent reporting discontinuity before relying on multi-year comparisons. The sharp changes in assets, equity and share counts between the earlier Avidity statements and the Q2 2026 statements may reflect a restatement, restructuring, merger or a change in the reporting entity, but the provided data does not explain the difference.